Exocrine Pancreatic Insufficiency
(EPI) Therapeutics Market – Regional Analysis
Geographically, the global Exocrine
Pancreatic Insufficiency (EPI) Therapeutics Market is segmented into North
America, Latin America, Europe, Middle East, Asia Pacific, and Africa. North
America is expected to dominate the global exocrine pancreatic insufficiency
(EPI) therapeutics market due to increasing incidence and prevalence cases of
these conditions occurring in this region. EPI is mostly characterized with its
associated conditions such as cystic fibrosis, pancreatic cancer, chronic
pancreatitis, gastrointestinal surgery, and others.
Exocrine pancreatic insufficiency
(EPI) is a condition associated with deficiency of exocrine pancreatic enzymes
that results in the inability to digest food or maldigestion. EPI may be
associated with certain diseases and conditions that affect the pancreas such
as cystic fibrosis, chronic pancreatitis, Shwachman–Diamond syndrome, and
others. Chronic pancreatitis (CP) is the most common cause of EPI in adults
that is followed by cystic fibrosis (CF). CF is an inherited genetic condition
that leads to chronic disease, which affects lungs, digestive, and reproductive
system. Patients suffering from exocrine pancreatic insufficiency cannot
properly digest proteins, fats, and carbohydrates in the food that results in
poor absorption of nutrients in the body.
Furthermore, EPI is associated
with uncomfortable gastrointestinal (GI) symptoms such as bloating, gas, and
oily diarrhea that floats and is difficult to flush. The symptoms of EPI may be
similar to other gastrointestinal disorders such as Crohn’s disease, celiac
disease, irritable bowel syndrome (IBS), ulcerative colitis, and small
intestinal bacterial overgrowth (SIBO), which makes EPI difficult to diagnose. However, there are
three major tests used for diagnosis of EPI that include, fecal elastase test,
fecal fat test, and direct pancreatic function test.
* The sample copy includes:
Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report
Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/2020
Exocrine Pancreatic Insufficiency
(EPI) Therapeutics Market – Drivers
Exocrine pancreatic insufficiency
is associated with certain diseases and conditions such as chronic
pancreatitis, cystic fibrosis, pancreatectomy, pancreatic cancer,
gastrointestinal surgery, type I and type III C diabetes, and other conditions
including autoimmune pancreatitis, celiac disease, and inflammatory bowel
disease. Moreover, high prevalence of these conditions leads to EPI, which in
turn fuels growth of exocrine pancreatic insufficiency (EPI) therapeutics
market. For instance, according to a report by the Cystic Fibrosis Foundation,
2010, around 1,000 new cases of cystic fibrosis are diagnosed globally every year.
Furthermore, according to a
report by the American Lung Association, 2010, cystic fibrosis is the second
most inherited disorder in infants in the U.S. The report further stated that
around 10 million cases in the U.S are symptomless carriers of the defective
cystic fibrosis gene and around 3,708 deaths were reported due to cystic
fibrosis between 1999 and 2006. Moreover, pancreatic cancer is a major factor
that leads to EPI. According to Cancer
Research UK 2015, around 9,800 new pancreatic cancer cases were registered in
the U.K. annually, from 2013 to 2015. The report further stated that pancreatic
cancer is the 11th most common cancer in the U.K. that accounted for 3% of all
new cancer cases, in 2015.
According to the American Cancer
Society (ACS), in the U.S 2018, around 55, 440 people are expected to be
diagnosed with pancreatic cancer, and around 44,330 people are expected to
succumb to pancreatic cancer. Furthermore, according to the National Cancer
Institute, from 2011 to 2015, 12.6 per 100,000 new cases of pancreatic cancer
were registered, annually, in the U.S.
Browse Research
Report: https://www.coherentmarketinsights.com/ongoing-insight/exocrine-pancreatic-insufficiency-epi-therapeutics-market-2020
According to a report by the
Diabetes.co.uk, 2018, EPI was more evident in the people with insulin-dependent
diabetes. According to the same source, in 2003, a study conducted on around
1,000 diabetic patients found that insulin-dependent diabetes was more likely
to produce abnormally low levels of exocrine pancreatic enzymes. Furthermore,
between 25% and 50% of insulin-dependent diabetes patients were found to have
developed exocrine pancreatic insufficiency. Moreover, high prevalence of
diabetes may increase the risk of EPI. For instance, according to International
Diabetes Federation (IDF) Diabetes Atlas: 2017, number of people with diabetes,
worldwide, aged between 20 to 79 years in 2017 was around US$ 425 million, and the number is estimated
to increase to 48% in 2045, accounting for around US$ 629 million.
Exocrine Pancreatic Insufficiency
(EPI) Therapeutics Market – Competitive Analysis
Key players operating in the
exocrine pancreatic insufficiency (EPI) therapeutics market include, AbbVie,
Inc., Digestive Care, Inc., Janssen Pharmaceuticals, Inc., Anthera
Pharmaceuticals, Inc., Allergan plc, AzurRx BioPharma, Inc., and others. Key
players operating in this market are focused on product regulatory approvals
and acquisition strategies to enhance their share in the market. For instance,
in May 2013, AbbVie, Inc. announced the availability of CREON (pancrelipase)
36,000 Lipase-unit Capsules for patients with EPI in the U.S. Furthermore, in
May 2018, VIVUS, Inc. entered into definitive agreement with Janssen
Pharmaceuticals, Inc. to acquire all the product rights for PANCREAZE
(pancrelipase) delayed-release capsules in the U.S. and Canada.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/2020
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
No comments:
Post a Comment